Androstenedione

A high androstenedione is the result that sends most people to this page, and the honest answer is that it localizes the problem to the steroid line without naming the room. The number is elevated because something upstream is pushing more raw material through the androgen pathway. The next question, the one the single value cannot answer, is which of the two factories is responsible.

That is because androstenedione draws from two separately regulated sources feeding one serum pool. According to Labcorp, adrenal production is controlled by ACTH, while gonadal production in the ovaries or testes is governed by the gonadotropins LH and FSH. Both empty into the same circulating level, so a high reading is a shared signal. Sorting out the source usually means looking at the company it keeps, such as DHEA-S as a more adrenal-leaning marker, or measuring 17-hydroxyprogesterone when an enzyme block is in question.

For a sense of scale, a result around 3 ng/mL sits near the top of the suggested PCOS band and well above the general adult range, while a figure such as 200 ng/dl in a woman (that is 2 ng/mL) lands above the typical female range. Some clinicians also read the androstenedione to testosterone ratio rather than either number alone, since a high ratio points more toward the adrenal side of the pathway.

The pattern worth knowing is that androstenedione can be high while testosterone reads normal. Because the intermediate sits upstream of the finished hormone, the line can overproduce the part on the bench without the final product breaching its range, particularly when the excess is adrenal. That mismatch is a feature: it is the reason a clinician sometimes orders the intermediate rather than relying on testosterone alone.

Congenital adrenal hyperplasia is where androstenedione's bench position pays off most clearly. In 21-hydroxylase deficiency, the most common form, the enzyme block stalls cortisol production. The precursors that would have become cortisol back up and spill down the androgen pathway instead, raising 17-hydroxyprogesterone first and androstenedione after it. The Endocrine Society's clinical practice guideline describes exactly this precursor shunt, which makes a rising androstenedione a marker of where the steroid line is overproducing.

For tracking whether treatment is working, the guideline names 17-OHP plus androstenedione, alongside testosterone, as the best indicators of whether glucocorticoid replacement is adequate. Here is the catch that explains the whole page. The guideline also notes that testosterone in men normally reflects the testes rather than the adrenal glands, so it is not useful for monitoring adrenal therapy in men. Androstenedione has no such blind spot. Because it is the cross-sex intermediate the adrenal line produces, it works as an adrenal-control marker in both men and women, doing the monitoring job that testosterone cannot do in half the patients. That is the difference between a hormone you total up and one whose value is positional.

On its own, androstenedione is a number that says the line is running hot without naming the product. It earns its place inside a hormone panel, read next to its neighbors so the source becomes legible: SHBG and cortisol shape how the androgens behave and how the adrenal axis is running. If your question is about the active androgen itself rather than the intermediate, the comparison of total versus free testosterone is the more direct read, and the female hormone panel guide walks through how these markers sit together when the picture involves excess hair growth or irregular periods.

The single value is a starting point, not a verdict. Because the ranges depend on age, sex, assay, and the time of the draw, what a given androstenedione means is a conversation for your doctor, who reads it positionally, as a sign of where the steroid line is working harder than it should.